TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced the appointment of Mr. Paul Slater as its Vice President, Sales and Marketing. Mr. Slater comes to Cambridge Heart with extensive experience and success in advancing medical device sales.
Prior to this appointment, Mr. Slater was Director of Operations with Medical Imaging Resources (“MIR”) for the past two years with responsibility for day to day operations as well as strategic directions and new product development.
Prior to 2009, Mr. Slater was with Siemens Medical Solutions, Inc., where over his 21-year career there rose to the level of Regional Vice President with P&L responsibility achieving high double digit gains in sales with increased profitability, market coverage and market share.
Commenting on the new addition, Cambridge Heart CEO Ali Haghighi-Mood said, “Adding a sales and marketing professional with the credentials of Paul Slater is a strong step forward for the Company. His experience in managing sales organization in both large and small companies and his record of accomplishments in penetrating markets and growing sales is exactly the type of sales leadership that is needed by Cambridge Heart to broaden awareness and develop strong relationships with both users and distributors alike.”
Mr. Slater added, “I’m delighted to be part of a company whose technology could help save hundreds of thousands of lives. The compelling story behind Cambridge Heart represents an opportunity that is both emotionally rewarding and tremendously exciting. I look forward to seeing my efforts and those of the Company result in the broad adoption of this technology.”
About Cambridge Heart, Inc.
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans™ measurement technologies, including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.
Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB. http://www.cambridgeheart.com.
Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.